Answers are grounded in this paper and cite their sources.
The optimal approach for holding or bridging therapy (H/BT) prior to second line axicabtagene ciloleucel (axi-cel) remains undefined, and the prognostic impact of response to H/BT remains debated. Here, we characterize real-world H/BT strategies and evaluate the impact of response on outcome following axi-cel infusion in the second-line setting for relapse or refractory (R/R) large B-cell lymphoma (LBCL). We included all adults with R/R LBCL within 12 months of first-line therapy who received axi-cel in the nationwide French DESCAR-T cohort (NCT04328298). The primary objective was to EFS between H/BT responders and nonresponders, as per Lugano criteria, using propensity score matching (PSM). Secondary objectives were to characterize H/BT modalities, corresponding responses, and to identify predictors of EFS at infusion. Among 566 patients included, 469 (83%) received chemotherapy-based H/BT, while 97 (17%) received a chemo-free approach, including no H/BT. Patients treated with chemotherapy-based H/BT had more advanced disease characteristics and exhibited inferior EFS compared to those receiving chemo-free approaches. After PSM, OS was significantly improved in responders versus non-responders (HR=0·70 [95% CI 0·51-0·96], p=0·0292), while the EFS benefit no longer reached statistical significance (HR=0·86 [95%CI 0·70-1·07], p=0·1739). Given that only patients ultimately receiving axi-cel were analyzed, the impact of H/BT response may have been underestimated. A predictive score combining response to H/BT, international prognostic index, LDH, and CRP at infusion identified two risk groups with significantly different EFS. In conclusion, H/BT response appears to be associated with axi-cel outcomes particularly when combined to inflammatory markers and residual LDH.
No takes yet. Share an insight, caveat, or question.
Capes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: